On August 3, ORIC Pharmaceuticals (NASDAQ:ORIC) reported second-quarter results that showed a clinical-stage biotech converting years of early work into two separate late-stage bets at once. The company started Himalayas-1, a global Phase 3 trial of its lead prostate cancer drug rinzimetostat, while holding $387.6 million in cash and investments to fund the effort. That combination, a pivotal trial underway and years of runway behind it, is the whole story of the quarter.
A Late-Stage Pipeline Takes Shape
Himalayas-1 is designed to enroll roughly 600 patients across more than 250 sites in 25 countries, randomizing them 1:1 to rinzimetostat plus darolutamide against a physician’s choice of an androgen receptor inhibitor or docetaxel. The primary endpoint is radiographic progression-free survival, with overall survival tracked as the key secondary measure. ORIC finalized the protocol only after End-of-Phase 1 talks with the FDA and other global regulators, and it paired the launch with a supply deal with Bayer, which provides its approved drug NUBEQA at no cost for the trial. ORIC kept full global rights to rinzimetostat, so the arrangement adds a partner’s drug to the combination without handing over any of the underlying asset.
Preclinical data presented at AACR gave a scientific rationale for the approach, showing that PRC2 inhibition curbs how prostate tumors adapt and helps sustain the benefit patients get from AR inhibition. The company’s second program, enozertinib, is running four separate Phase 1b studies in EGFR-mutated lung cancer, covering exon 20 insertions and atypical mutations, both alone and paired with amivantamab or chemotherapy. Data from the atypical mutation study is scheduled for the ESMO Congress in October, with exon 20 monotherapy and combination results expected later in the year. ORIC says its cash position funds operations into the second half of 2028, which the company frames as carrying it past the first Himalayas-1 readout.
The Losses Keep Climbing
Running a 600-patient global trial costs money, and the expense lines show it. Research and development spending rose to $36.3 million for the quarter, up from $30.5 million a year earlier, an increase the company tied to rinzimetostat’s advancement even as enozertinib costs eased on manufacturing and clinical timing. General and administrative costs crept up too, to $9.0 million from $8.5 million, on higher personnel and professional service costs. Add it up, and the net loss widened to $41.5 million for the quarter from $36.4 million a year ago, with the six-month loss reaching $77.3 million versus $66.4 million.
ORIC covered part of that gap by raising $59.9 million in net proceeds through an at-the-market program during the first quarter, and its weighted average share count climbed from about 78.1 million shares to 108 million, an increase of nearly 40%. That dilution is why the loss per share actually narrowed, to $0.38 from $0.47, even though the total dollar loss grew. None of ORIC’s programs have produced pivotal data yet. Rinzimetostat just entered Phase 3, and enozertinib remains in Phase 1b, so the entire investment case still rests on trials that have not read out.
What The Market Is Pricing In
Hedge fund ownership slipped to 41 funds from 47 the prior quarter, a pullback that runs counter to a company that just started its first pivotal trial. Short interest sits at 16.83% of the float, a level that signals a meaningful bear camp rather than routine hedging. That combination of departing funds and heavy short positioning suggests the market is treating the Himalayas-1 launch with more caution than celebration.
Two Trials, One Runway
ORIC has spent this quarter turning a research pipeline into two live clinical bets, backed by enough cash to reach a first pivotal readout without needing new financing along the way. For the bulls, that runway plus a diversified, brain-penetrant lung cancer program alongside the prostate cancer trial is what justifies patience. For the bears, nearly 40% more shares outstanding and a widening loss are the price of getting there, with years still standing between today and any regulatory decision.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Hedge Fund Resource Center